Clinical Research
Filter News
Found 126,046 articles
-
The vaccine distribution has been paused in the country because of six or seven cases of rare blood clots.
-
Sponsored | Business Transformation during a Pandemic: Q&A about Jubilant Biosys’ bold plans wit...
4/19/2021
This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagu... -
As the U.S. reports surges in COVID-19 infections despite increased enrollment in vaccines, news continues to break about therapies, vaccines, and the risks involved with the new vaccines. Here’s a look.
-
LivaNova Achieves Clinical Milestone in Heart Failure Program
4/19/2021
LivaNova PLC (NASDAQ:LIVN), today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study,
-
Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control
4/19/2021
Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control Empowers women with personalized birth control recommendations aimed to minimize medication side effects, including blood clots and depression
-
NanoVibronix Announces Start of Real World Patient Study of UroShield
4/19/2021
Independent Study Being Led by Southampton University Health Sciences Patient Recruitment Underway; Interim Results Expected in October 2021
-
Probo Medical Acquires SonoDepot
4/19/2021
Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, announced today the acquisition of SonoDepot, Inc. (“SonoDepot”). Terms of the transaction were not disclosed.
-
Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population
4/19/2021
Inflammasome Therapeutics ( https://www.inflam.com ), a private company developing therapies for prevalent, degenerative diseases, reported newly published research continues to confirm the potential of the company’s proprietary Kamuvudines, to be an effective treatment for geographic atrophy (GA), a severe and untreatable form of age-related macular degeneration (AMD) that causes 20% of legal blindness in the US.
-
BioSpace, Inc. Acquires MedReps
4/19/2021
BioSpace, Inc. announced today it has acquired MedReps, the leading career platform for medical sales positions. The acquisition strengthens the Company's position as the leader in online recruitment for the life sciences industry.
-
Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 10th World Congress of Melanoma
4/19/2021
- Results demonstrated that the combination of [ 212 Pb] VMT01 and immune checkpoint inhibitors induced synergistic anti-tumor effect and 43% complete tumor responses - - Company is launching Phase 1 imaging study of VMT01 imminently with provisional results expected in Q4 2021, followed by Phase 1/2a therapy study for the treatment of metastatic melanoma -
-
Feinstein Institutes Scientists Develop Long-Term Vagus Nerve Implant for Bioelectronic Medicine Research
4/19/2021
Researchers at the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research developed a long-term implant model for vagus nerve stimulation (VNS) in mice that successfully modulates heart rate and inflammatory proteins. The device and procedure may change the way preclinical bioelectronic medicine research is conducted and lead to alternative therapies for various chronic diseases, includ
-
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
4/19/2021
First 10 patients dosed in 77 patient randomized, double blind, placebo controlled Phase 2 Clinical Trial at Shaare Zedek Medical Center in Jerusalem, Israel Data from randomized, placebo controlled, open label Phase 1b trial in 27 hospitalized COVID-19 patients supports dose selection for the Phase 2 Clinical Trial Company to include its proprietary 3CL protease enzymatic assay (“TolloTest™) as exploratory theranostic biomarker
-
Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
4/19/2021
Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.
-
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
4/19/2021
New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency
-
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal EpilepsyData presented at American Academy of Neuroscience (AAN) Annual Meeting
4/19/2021
Neurona Therapeutics , a biotherapeutics company advancing neural cell therapies for the treatment of neurological disorders, today announced the presentation of preclinical data from its lead inhibitory neuron cell therapy program, which is being developed for the treatment of drug-resistant focal epilepsy.
-
Sunshine Biopharma Reports Favorable MTD Results for COVID-19 Treatment
4/19/2021
Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dose (MTD) study in mice.
-
U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
4/19/2021
- RAGWITEK is now indicated to treat ragweed pollen allergy in children and adolescents five through 17 years of age, in addition to adults through 65 years of age - - Ragweed pollen is one of the most common allergens found in North America and affects approximately 23 million people in the U.S.1 -
-
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors
4/19/2021
Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug application (IND) for PVSRIPO in patients with solid tumors.
-
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
4/19/2021
Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV ® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
-
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
4/19/2021
Half of All Patients With NSCLC Have Oncogene Mutations, Yet Many Patients Are Not Tested to Screen for Biomarkers Professional Clinical Guidelines Recommend Broad Biomarker Testing for Actionable and Emerging Biomarkers, Including KRAS Biomarker Assist™ May Provide Eligible Patients Savings on Biomarker Testing